• Earlier in May 2026, Alvotech reported that the FDA completed a routine cGMP surveillance inspection of its Reykjavik manufacturing facility, issuing a Form 483 that the company believes involves addressable observations and supports resubmission of key Biologics License Applications this quarter.
• Management is framing the inspection outcome as validation of the site’s quality improvements and as support for its expectation of FDA decisions on the relevant BLAs during 2026, a crucial pillar for its biosimilar-led growth plans.
• We’ll now examine how the completed FDA inspection and planned BLA resubmissions could shape Alvotech’s existing investment narrative for 2026.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Alvotech Investment Narrative Recap

To own Alvotech, you need to believe its biosimilar portfolio can convert regulatory progress into durable, cash-generating products, despite high debt and volatile milestone income. The recent FDA inspection in Reykjavik, while resulting in a Form 483, appears manageable based on the company’s comments and keeps near term BLA resubmissions on track. That supports the key catalyst of potential 2026 FDA decisions, but regulatory execution remains the most immediate risk.

The updated 2026 revenue guidance of US$650 million to US$700 million, excluding any contribution from potential U.S. launches of AVT03, AVT05 or AVT06, is especially relevant here. It suggests management is not counting on near term U.S. approvals in its base case, which could help cushion the financial impact if FDA timelines slip again, but it also highlights how much upside and risk are tied to those pending BLAs.

Yet even if the Reykjavik inspection outcome looks constructive, investors should still be aware of how heavily Alvotech’s cash flow depends on timely FDA approvals and milestone payments...

Alvotech's narrative projects $980.5 million revenue and $189.6 million earnings by 2029.

Uncover how Alvotech's forecasts yield a $14.00 fair value, a 327% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts take a much harsher view of these FDA related risks, even while forecasting about US$968 million of revenue and US$80 million of earnings by 2029, so you should compare their assumptions with this inspection news and decide which version of Alvotech’s future feels more realistic.

Explore 5 other fair value estimates on Alvotech - why the stock might be worth just $4.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alvotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alvotech's overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.